Genmab A/S (OTCMKTS:GNMSF) Announces Quarterly Earnings Results, Beats Estimates By $1.43 EPS

Key Points

• Genmab A/S reported a quarterly earnings of $5.42 EPS, exceeding the consensus estimate of $3.99 EPS by $1.43.
• The company's revenue for the quarter was $925.00 million, falling short of analysts' expectations of $949.06 million.
• Genmab A/S has a market capitalization of $14.29 billion and a price-to-earnings ratio of 10.86.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $5.42 EPS for the quarter, topping the consensus estimate of $3.99 by $1.43, Zacks reports. The business had revenue of $925.00 million for the quarter, compared to analysts' expectations of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.23%.

Genmab A/S Price Performance

Genmab A/S stock opened at $216.31 on Friday. Genmab A/S has a 1-year low of $170.00 and a 1-year high of $282.06. The firm has a market capitalization of $14.29 billion, a P/E ratio of 10.86 and a beta of 0.93. The company's 50-day moving average is $215.25 and its 200 day moving average is $206.75.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.